Clinical Trial Update: CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating MAT2203 (CAMB) for chronic mucocutaneous candidiasis has completed and posted results as of 2024-06-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mucocutaneous Candidiasis

Drugs mentioned

• MAT2203

Snippet

Sponsor: Matinas BioPharma Nanotechnologies, Inc. | Conditions: Candidiasis, Chronic Mucocutaneous | Phase 2 | Status: COMPLETED | Results posted: 2024-06-07